Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides
Conditions
- CD30 Positive Cutaneous T Cell Lymphoma
- CD30 Positive Transformed Mycosis Fungoides
Interventions
- GENETIC: Genetically modified T cells # 1138
Sponsor
University of Cologne